Thymosin Alpha-1: an Italian immunopeptide and the trial that rewrote its story.

There is a class of compounds whose mechanism is best understood as conducting rather than amplifying. Thymosin Alpha-1, a 28-amino-acid peptide originally isolated from the calf thymus by Allan Goldstein in the 1970s and brought to market as the synthetic drug Zadaxin (thymalfasin), has been studied for half a century, approved in dozens of countries, and used in tens of millions of patient-courses for chronic hepatitis B, hepatitis C, and as an adjuvant for chemotherapy and vaccination. What it does, broadly, is shift the immune set-point. Where the system is suppressed, it lifts. Where it is hyperactive, it dampens.

Origin and chemistry

Allan Goldstein's group at the University of Texas Medical Branch sequenced thymosin alpha-1 in 1977 from thymic tissue, identifying a 28-residue acidic peptide with N-terminal acetylation. The synthetic version reached clinical use in Italy in 1989 under the trade name Zadaxin (thymalfasin), manufactured by SciClone Pharmaceuticals. Italian peptide chemistry — particularly the work coming out of the University of Florence's Department of Chemistry under Anna Maria Papini and Paolo Rovero — has remained central to the field.

Mechanistically, Tα1 binds Toll-like receptor 9 on plasmacytoid dendritic cells and TLR2 on macrophages, increases CD4+ and CD8+ T-cell maturation, restores natural killer cell activity in immunosuppressed states, and dampens regulatory T-cell expansion when those cells are pathologically high. Cytokine effects are bidirectional: pro-inflammatory cytokines tend to fall in hyperinflammatory states; anti-inflammatory IL-10 and TGF-β fall in immunosuppressed states. The conducting metaphor is not loose.

The 2025 BMJ trial that complicated the sepsis story

For two decades, meta-analyses of Tα1 in sepsis suggested a meaningful 28-day mortality benefit. In January 2025, Jianfeng Wu, Xiangdong Guan, and colleagues at the First Affiliated Hospital of Sun Yat-sen University in Guangzhou published the answer in BMJ. The TESTS trial — multicenter, double-blind, placebo-controlled, 1,106 adults across 22 Chinese centers — found no statistically significant reduction in 28-day all-cause mortality. On the primary endpoint, the trial was negative.

The prespecified subgroup analyses, however, revealed something the earlier meta-analyses had not had the statistical power to see. In patients aged 60 or older, the hazard ratio was 0.81; in patients younger than 60, it was 1.67. In patients with diabetes, the hazard ratio was 0.58 (a 42 percent mortality reduction). The interaction p-values were significant. The drug works in some sepsis populations and may be neutral or harmful in others.

What works clearly: hepatology

The cleanest signals for Tα1 remain in liver disease. A March 2026 randomized controlled trial from Bing-Liang Lin's group at the Third Affiliated Hospital of Sun Yat-sen University, in Immunopharmacology and Immunotoxicology, enrolled 73 patients with hepatitis B virus-related acute-on-chronic liver failure. The Tα1 arm showed significantly higher 90-day transplant-free survival. The mechanism, as profiled by flow cytometry and serum cytokine analysis, was rebalancing: regulatory T-cell frequencies came down; effector T-cell frequencies came up.

A separate propensity-matched analysis from West China Hospital at Sichuan University, published in Medicine in 2021, examined 468 patients with solitary HBV-related hepatocellular carcinoma after curative liver resection. Tα1 adjuvant therapy was an independent predictor of overall survival (hazard ratio 0.31) and recurrence-free survival (hazard ratio 0.38).

The peptide does not eradicate hepatitis B. It rebuilds the immune coordination the virus has dismantled. The clinical question is whether that coordination is enough.

Beyond the obvious

Two adjacent findings are worth noting. The first comes from Beijing You-An Hospital at Capital Medical University: in HBV patients with covalently closed circular DNA — the viral reservoir that current antivirals cannot touch — Tα1 (combined with thymopentin in this 2019 study) accelerated HBsAg decline beyond what entecavir plus pegylated interferon achieved alone. The second is the eye disease application — a thread the Italian peptide chemistry community at Florence has pursued, with Tα1 modifications targeting dry eye disease and ocular surface inflammation.

Often studied alongside

Adjacent research has paired Tα1 with the KLOW peptide stack — BPC-157, TB-500, GHK-Cu, KPV — in protocols focused on immune-tissue interactions during recovery from chronic infection or post-surgical states. The pairing logic is that KLOW's tissue-repair signaling depends on a non-hostile immune environment, which Tα1 helps re-establish. Researchers studying chronic hepatitis B have placed Tα1 alongside Selank in protocols where vagal-mediated anxiolysis is a confound in immune-recovery studies.

Practical considerations

Tα1 is supplied as a lyophilized powder. The peptide tolerates lyophilized storage at −20°C well; reconstituted material should be refrigerated and used within the manufacturer-specified window. All Precursor catalog entries are sold for research use only — not medicines, not approved for human consumption, not evaluated by the FDA, EMA, MHRA, or any equivalent regulator.